Dr. Mateos on Ixazomib-Lenalidomide-Dexamethasone in Multiple Myeloma

Maria-Victoria Mateos, MD, PhD
Published: Monday, Jul 11, 2016


Maria-Victoria Mateos, MD, PhD, consultant physician, hematology department, Hospital Universitario de Salamanca, discusses ixazomib-lenalidomide-dexamethasone in multiple myeloma.
 
The trial demonstrated that the oral regiman ixazomib-lenalidomide-dexamethasone (IRd) improved progression-free survival (PFS) compared to placebo plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).  
 
In the past, lenalidomide-dexamethasone was the standard of care, but now there are numerous options for three-drug combinations for patients that have relapsed after one to three prior lines of therapy, says Mateos.
 
There may be challenges selecting the right three-drug combination, as results are similar between them. The main advantage of IRd is that it is an all oral combination, requiring less hospital visits, says Mateos.
 

Maria-Victoria Mateos, MD, PhD, consultant physician, hematology department, Hospital Universitario de Salamanca, discusses ixazomib-lenalidomide-dexamethasone in multiple myeloma.
 
The trial demonstrated that the oral regiman ixazomib-lenalidomide-dexamethasone (IRd) improved progression-free survival (PFS) compared to placebo plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).  
 
In the past, lenalidomide-dexamethasone was the standard of care, but now there are numerous options for three-drug combinations for patients that have relapsed after one to three prior lines of therapy, says Mateos.
 
There may be challenges selecting the right three-drug combination, as results are similar between them. The main advantage of IRd is that it is an all oral combination, requiring less hospital visits, says Mateos.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x